FDA Inspection 1263915 — Tubilux Pharma Spa

Tubilux Pharma Spa — FEI 3003854110

The FDA completed an inspection of Tubilux Pharma Spa on Jun 14, 2024 in Pomezia. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Jun 14, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Pomezia (Italy)

Additional Details

Mutual Recognition Agreement (MRA)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.